Tocilizumab Generics - Manufacturers & Suppliers
Actemra®(US); RoActemra®(EU)
| Product/Composition:- | Tocilizumab |
|---|---|
| Strength:- | IV: 80 mg/4 mL, 200 mg/10 mL, 400 mg/20 mL; SQ: 162 mg/0.9 mL (pen or syringe) |
| Form:- | IV injection, SQ Injection |
| Reference Brands:- | Actemra®(US); RoActemra®(EU) |
| MOQ | As per the manufacturer batch size |
| Get Quote Send Enquiry on WhatsApp | |
Tocilizumab (brand: Actemra by Roche) is an IL-6 receptor antagonist approved in the US, EU, and several global markets for severe COVID-19 and rheumatoid arthritis. Available in IV and subcutaneous forms, it’s in high demand for hospital use. Global PharmaB2B networks link buyers with verified Tocilizumab exporters and manufacturers, offering compliant sourcing, secure logistics, and international distribution support.
Tocilizumab (brand name Actemra or RoActemra) is a monoclonal antibody used to treat severe COVID-19 complications and autoimmune conditions like rheumatoid arthritis. Available in intravenous (IV) and subcutaneous (SC) forms, it comes in strengths such as 80 mg, 200 mg, 400 mg IV vials, and 162 mg SC pens/syringes. Approved in the US, EU, and global markets, Tocilizumab is in high demand for hospitals and critical care. Through trusted PharmaB2B platforms, buyers can connect with certified Tocilizumab manufacturers, exporters, and distributors, ensuring regulatory-compliant sourcing, bulk availability, and fast international delivery for institutional and government tenders.